Clinical trial demonstrates that elinzanetant relieves vasomotor symptoms and sleep disturbance in postmenopausal women, highlighting its viability as an effective nonhormonal therapy.
Elinzanetant is an effective and well-tolerated nonhormone treatment option for postmenopausal women with VMS and associated sleep disturbance. Elinzanetant also improves quality of life in women with VMS.
No takes yet. Share an insight, caveat, or question.
Simon et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: